- Research Article
1
- 10.1016/j.jsames.2026.105955
The Mesoarchean Algodoeiro Metagranite: a new piece in the Araçuaí Orogen basement inliers puzzle
- Mar 01, 2026
- Journal of South American Earth Sciences
- Geysianne Morais + 5 more +5
Publications from 2021 to 2026
Showing 10 of 74 papers
The Mesoarchean Algodoeiro Metagranite: a new piece in the Araçuaí Orogen basement inliers puzzle
Impact of lung cancer screening eligibility criteria on participants' characteristics and healthcare resources.
Selection criteria for lung cancer screening (LCS) are essential for implementing resource- and cost-efficient programs. However, different selection criteria may have similar resource requirements but select dissimilar individuals. This study explores the impact of inclusion criteria on participants' characteristics and health services in Spain. A cross-sectional study was conducted using data from 21,007 individuals from the 2012 Spanish National Health Survey. LCS eligibility was evaluated for four criteria: two from the 4-IN-THE-LUNG-RUN trial (4ITLR1: ages 60-79, 35 pack-years, current smokers or <10 years since cessation; 4ITLR2: ages 60-79, PLCOm2012noRace risk ≥2.6%), the United Kingdom's Targeted Lung Health Check (TLHC: ages 55-74, PLCOm2012noRace risk ≥1.51%), and the United States Preventive Services Task Force (USPSTF: ages 50-80, 20 pack-years, current smokers or <15 years since cessation). Under the most restrictive (4ITLR1) 5.6% of ages 50-80 were eligible, requiring 9.0% additional radiological capacity. Under the broadest (USPSTF) 21.6% of ages 50-80 were eligible, requiring 34.2% additional capacity. All criteria primarily selected men (68.1-82.2% of eligibles). Most criteria favored selecting former smokers (49.4-56.9%). However, eligible women were more often current smokers than men across all criteria (men: 38.5-46.8%, women: 52.7-66.5%). Former smokers smoked more cigarettes per day than current smokers (30 vs. 20) despite having shorter smoking durations, resulting in higher median pack-years across all criteria (range: 44-66). Overall, pack-year-based eligibility decreased with age, while risk-based eligibility was stable across age groups. Different LCS criteria yield populations with highly varied characteristics. Risk-based criteria may provide more equitable eligibility across age groups.
Read moreNeeds and opportunities for improvement in the management and monitoring of gynaecological cancer in Spain.
The primary objective of this study is to identify opportunities to improve clinical and comprehensive support of patients diagnosed with gynaecological cancers in Spain. Secondary objectives included identifying the unmet needs regarding awareness and access to screening strategies of gynaecological cancers in Spain. A mixed-methods design was used, combining qualitative and quantitative research in 235 participants. The qualitative component comprised semi-structured interviews and focus groups with 12 patients with gynaecological cancer, 6 caregivers, and 11 healthcare professionals. The quantitative component included anonymous surveys from 44 women with gynaecological cancer and 162 women from the general population. Descriptive statistics were applied. The qualitative study revealed needs in prevention, early diagnosis, emotional support, nutrition, physical activity, and sexual health. Among surveyed patients, the mean knowledge of gynaecological cancer before diagnosis was low (2.3/6). Substantial limitations were reported after diagnosis in physical activity (59%), diet (43%), and sexual life (70%), and 55% experienced psychological consequences. Fifty-six percent reported insufficient non-pharmacological information from their healthcare team, and 59% sought support from patient associations. In the general population, 40% of women had never received information on gynaecological cancer. Improving care for women with gynaecological cancers in Spain requires action at two levels: (1) strengthened early detection through awareness and screening strategies, and (2) expanded supportive services including nutrition, psycho-oncology, physical activity programmes, and sexual health interventions. Addressing taboos around women's sexuality and leveraging patient associations and preferred communication channels should be priorities.
Read moreModulating the Gut Microbiota via Rectal Ozone Insufflation in Gynecological Cancer Patients with Radiotherapy/Chemotherapy-Induced Pelvic Toxicity: A Proposed Clinical Study Protocol
Background: Chronic pelvic toxicity induced by radiotherapy and/or chemotherapy (R/CIPT) is a debilitating sequela in gynecological cancer survivors, often refractory to conventional treatments and potentially linked to gut microbiota dysbiosis. Ozone therapy (OT), particularly rectal insufflation, demonstrates anti-inflammatory and redox-modulating effects through hormetic mechanisms (Nrf2 activation/NF-κB inhibition). We hypothesize that its clinical benefit is mediated, in part, by restoring gut microbial homeostasis. Objective: This manuscript proposes a clinical study to evaluate the impact of rectal OT on the gut microbiota of patients with gynecological cancers and chronic R/CIPT. Proposed Methods: A prospective, observational study of 38 patients is outlined: 19 with CTCAE v5.0 Grade ≥2 chronic R/CIPT receiving compassionate rectal OT (~40 sessions over 4 months), and 19 matched controls without toxicity. Stool samples for 16S rRNA sequencing will be collected from the OT group pre- and post-intervention and once from controls. Primary endpoints are changes in microbiota composition/diversity and pelvic toxicity scores (CTCAE v5.0, EORTC QLQ-CX24). Secondary endpoints include quality of life (EORTC QLQ-C30, EQ-5D-5L), anxiety/depression (HADS), and serum inflammatory/oxidative stress biomarker analysis. Anticipated Results and Conclusion: This will be the first study to prospectively investigate whether rectal OT’s effect correlates with a beneficial shift in the gut microbiota, specifically an increase in commensals (e.g., short-chain fatty acids producers) and a decrease in pathobionts. If successful, OT could be assessed as a novel, microbiota-targeting intervention for R/CIPT. The findings from this pilot study will provide the necessary groundwork for a future randomized controlled trial to definitively establish causality and efficacy.
Read moreLONG-TERM FOLLOW-UP OF SELINEXOR MAINTENANCE TREATMENT IN PATIENTS WITH TP53 WILD TYPE ADVANCED/RECURRENT ENDOMETRIAL CANCER: INTERMEDIATE ENDPOINTS BY MISMATCH REPAIR STATUS IN THE ENGOT-EN5/GOG-3055/SIENDO STUDY
P1.11.07 Impact of Radiotherapy and Immune Checkpoint Inhibitor Combination in Advanced NSCLC: Real-World Data (RWD) Analysis
Smart Sensor Networks for Breast Cancer Screening and Monitoring
Breast cancer remains one of the leading causes of cancer-related mortality among women worldwide. Early detection through regular screening significantly improves treatment outcomes and survival rates. This paper presents a novel smart sensor network architecture for breast cancer screening and monitoring, leveraging Internet of Things (IoT) technologies, machine learning algorithms, and wearable sensors. Our proposed system integrates multiple sensing modalities including thermography, ultrasound, and bio-impedance measurements to provide continuous, non-invasive monitoring capabilities. The network architecture employs edge computing for real-time data processing and cloud-based analytics for comprehensive health assessment. Experimental results demonstrate 94.2% accuracy in detecting suspicious tissue changes, with a false positive rate of 6.8%. The system also achieves significant improvements in patient comfort and accessibility compared to traditional screening methods. This research contributes to the advancement of personalized healthcare and early cancer detection through innovative sensor network technologies.
Read morePrimary Analysis of EPIK-O/ENGOT-ov61: Alpelisib Plus Olaparib Versus Chemotherapy in Platinum-Resistant or Platinum-Refractory High-Grade Serous Ovarian Cancer Without BRCA Mutation.
Patients with platinum-resistant/platinum-refractory high-grade serous ovarian cancer (HGSOC) without a BRCA mutation have poor prognosis and limited treatment options. We report efficacy and biomarker data from EPIK-O, which investigated alpelisib + olaparib versus single-agent chemotherapy in these patients. EPIK-O was an open-label, phase III trial that randomly assigned patients with platinum-resistant/platinum-refractory HGSOC with no germline or known somatic BRCA mutation 1:1 to alpelisib 200 mg once daily + olaparib 200 mg twice daily or treatment of physician's choice (TPC; paclitaxel 80 mg/m2 once weekly or pegylated liposomal doxorubicin 40-50 mg/m2 once every 28 days). Patients had 1-3 previous systemic therapies. Previous bevacizumab was required (unless contraindicated); previous poly(adenosine diphosphate-ribose) polymerase inhibitors were allowed. Primary end point was progression-free survival (PFS) per RECIST 1.1 (blinded independent review committee [BIRC]). Secondary efficacy end points included overall response rate (ORR; per BIRC), duration of response (per BIRC), and overall survival (OS; key secondary end point). A total of 358 patients (alpelisib + olaparib [n = 180], TPC [n = 178]) were included. The median follow-up time was 9.3 months. At data cutoff (April 21, 2023), 33 (18.3%) and 30 (16.9%) patients remained on treatment with alpelisib + olaparib and TPC, respectively. The median PFS (BIRC) was 3.6 versus 3.9 months (hazard ratio [HR], 1.14 [95% CI, 0.88 to 1.48]; one-sided P = .84) for alpelisib + olaparib versus TPC. The ORR was 15.6% (95% CI, 10.6% to 21.7%) versus 13.5% (95% CI, 8.8% to 19.4%). The median OS was 10.0 versus 10.6 months (HR, 1.22; 95% CI, 0.87 to 1.71). The safety profile of alpelisib + olaparib was consistent with that observed for the individual agents. The primary objective, PFS improvement, was not met in EPIK-O. No new or unexpected adverse events were observed. Biomarker analyses provided new insights for responders to alpelisib + olaparib.
Read morePilot Transcriptomic Profiling of Canine Oral Melanoma Reveals Conserved Oncogenic Pathways and Uncharacterized Molecular Signatures.
Canine oral melanoma (COM) is an aggressive and often fatal neoplasm in dogs, with clinical and molecular similarities to human melanoma. Despite its relevance as a comparative oncology model, the molecular mechanisms underlying COM remain poorly understood. This study aimed to characterize gene expression profiles in COM to identify differentially expressed genes (DEGs), potential biomarkers, and therapeutic targets. In this pilot study, we performed RNA sequencing (RNA-seq) on tumor and healthy oral tissue samples from dogs. Two independent analytical pipelines-Bowtie2-DESeq2 and HISAT-StringTie-Ballgown-were used to ensure robustness in DEG detection. We also conducted pathway enrichment and isoform-level analyses to investigate biological processes and alternative splicing events. Both approaches identified a core set of 929 common DEGs. Key oncogenic pathways, including MAPK/ERK and cell cycle regulation, were significantly affected, with notable upregulation of BRAF, NRAS, CDK4, and MITF (log2FC = 2.86, p < 0.001). The transcription factor SOX10 and the cytokine IL-33, both previously implicated in melanoma progression, were consistently overexpressed. Additionally, NF1, a known RAS pathway inhibitor, was also upregulated. Isoform analysis revealed novel transcript variants, suggesting a complex layer of post-transcriptional regulation in COM. Many DEGs remained uncharacterized, and chromosomal distribution analysis highlighted potential genomic influences. Our findings provide new insights into the molecular landscape of COM, reinforcing its utility as a model for human melanoma. The identification of conserved oncogenic pathways and novel transcript variants opens avenues for further functional studies and the development of targeted therapies in both veterinary and human oncology.
Read moreA randomised non-comparative phase II study of atezolizumab, bevacizumab and chemotherapy in EGFR-mutant NSCLC with acquired resistance - The ETOP 15-19 ABC-lung trial.